Torrent Pharmaceuticals Limited on Monday announced that it has entered into a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan in India.
According to the company’s statement, Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders-Gastroesophageal Reflux Disease (GERD). Torrent will market Vonoprazan under its trademark, Kabvie.
As per a 2019 study published by the Indian Journal of Gastroenterology prevalence of GERD in the Indian population is around 8.2 percent, with a higher prevalence of around 11.1% in the urban population.
According to AWACS MAT April 2024 data, the Indian market for treatments used in GERD is valued at INR 8,064 crore, growing at 8 percent CAGR over the last 4 years. Currently, treatments such as Pantoprazole (Proton Pump Inhibitors) are used to treat GERD. Availability of P-CABs such as Kabvie will make accessible new and effective treatments of GERD for the Indian population.
“We are delighted to commercialize this novel treatment for Indian patients. I am confident that the launch of Kabvie will aid in reducing the disease burden of GERD and further strengthen our Gastrointestinal offerings, augmenting our position as a leading player within the Indian Pharmaceutical Market,” Commenting on the agreement, Aman Mehta – Director, Torrent said in a statement.
